桂枝茯苓汤辨证加味对晚期宫颈癌化学药物治疗患者的增效减毒作用

doi:10.3969/j.issn.1006-7795.2018.04.022

首都医科大学学报 ›› 2018, Vol. 39 ›› Issue (4): 596-601.doi: 10.3969/j.issn.1006-7795.2018.04.022

桂枝茯苓汤辨证加味对晚期宫颈癌化学药物治疗患者的增效减毒作用

常忠莲¹, 盛晓滨², 石新兰³, 韦薇¹

1. 首都医科大学石景山教学医院北京市石景山医院中医科, 北京 100043;
2. 首都医科大学石景山教学医院北京市石景山医院妇科, 北京 100043;
3. 首都医科大学石景山教学医院北京市石景山医院病理科, 北京 100043

收稿日期:2018-04-02 出版日期:2018-07-21 发布日期:2018-07-21
通讯作者: 常忠莲 E-mail:changzlusa@sina.com

Effect of synergism and attenuation of Guizhi Fuling decoction in patients with advanced cervical cancer treated with chemotherapy

Chang Zhonglian¹, Sheng Xiaobin², Shi Xinlan³, Wei Wei¹

1. Department of Traditional Chinese Medicine, Beijing Shijingshan Teaching Hospital, Capital Medical University, Beijing Shijingshan Hospital, Beijing 100043, China;
2. Department of Gynaecology, Beijing Shijingshan Teaching Hospital, Capital Medical University, Beijing Shijingshan Hospital, Beijing 100043, China;
3. Department of Pathology, Beijing Shijingshan Teaching Hospital, Capital Medical University, Beijing Shijingshan Hospital, Beijing 100043, China

Received:2018-04-02 Online:2018-07-21 Published:2018-07-21

摘要/Abstract

摘要： 目的探讨桂枝茯苓汤辨证加味对晚期宫颈癌化学药物治疗（以下简称化疗）患者的增效减毒作用。方法选取2015年2月至2017年3月收治的晚期宫颈癌患者84例，利用数字表法随机将其分为单一组及联合组，各42例。单一组给予紫杉醇+顺铂（taxinol plus platinum，TP）化疗方案治疗，联合组在单一组基础上给予桂枝茯苓汤辨证加味治疗。对比两组患者临床疗效，且均于治疗前后抽取外周静脉血，检测并比较治疗前后血清免疫球蛋白（IgG、IgA、IgM）和T淋巴细胞亚群（CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺）的变化，并对比两组患者不良反应发生情况。结果两组临床疗效等级分布比较差异有统计学意义（P<0.05），且联合组临床获益率明显高于单一组（P<0.05）；单一组治疗后血清IgG、IgA、IgM、CD3⁺、CD4⁺、CD4⁺/CD8⁺均明显低于治疗前（P<0.05），CD8⁺明显高于治疗前（P<0.05），但联合组治疗前后血清IgG、IgA、IgM、CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺均差异无统计学意义（P>0.05），且联合组治疗后血清IgG、IgA、IgM、CD3⁺、CD4⁺、CD4⁺/CD8⁺均明显高于单一组（P<0.05），CD8⁺明显低于单一组（P<0.05）；联合组骨髓抑制、直肠刺激反应、皮肤反应及膀胱刺激反应发生率均明显低于单一组（P<0.05）。结论桂枝茯苓汤辨证加味应用于晚期宫颈癌化疗患者，可显著提高临床疗效，维持机体免疫功能稳定，并减少不良反应。

关键词: 桂枝茯苓汤, 晚期宫颈癌, 临床疗效, 不良反应

Abstract: Objective To investigate the effect of synergism and attenuation of Guizhi Fuling decoction in patients with advanced cervical cancer treated with chemotherapy. Methods Eighty-four patients with advanced cervical cancer were admitted from February 2015 to March 2017, who were divided into single group and combination group by random digital table method, and there were 42 cases in each group. The single group was treated with taxinol plus platinum (TP) chemotherapy, while the combination group was treated with Guizhi Fuling decoction on the basis of the single group. The clinical effect was compared, and the peripheral blood samples of patients of the two groups before and after treatment were collected, then the levels of the serum immunoglobulin (IgG, IgA, IgM) and T lymphocyte subsets (CD3⁺, CD4⁺, CD8⁺, CD4⁺/CD8⁺) of the two groups were detected and compared, as well as the toxic and side reactions of patients. Results The grade distribution of the clinical effect between the two groups had a significant difference (P<0.05), and the clinical benefit rate (CBR) of the combination group was significantly higher than that of the single group (P<0.05). The levels of serum IgG, IgA, IgM, CD3⁺, CD4⁺ and CD4⁺/CD8⁺ of the single group after treatment were significantly lower than those before treatment (P<0.05), and CD8⁺ of the single group after treatment was significantly higher than that before treatment (P<0.05), but the levels of serum IgG, IgA, IgM, CD3⁺, CD4⁺, CD8⁺ and CD4⁺/CD8⁺ of the combination group before treatment and after treatment showed no significant differences (P>0.05), and the levels of serum IgG, IgA, IgM, CD3⁺, CD4⁺ and CD4⁺/CD8⁺ of the combination group after treatment were significantly higher than those of the single group (P<0.05), but CD8+ was significantly lower than that of the single group (P<0.05). The incidence rates of bone marrow suppression, rectal irritation, skin reaction and bladder irritation of the combination group were significantly lower than those of the single group (P<0.05). Conclusion Guizhi Fuling decoction in the treatment of advanced cervical cancer patients with chemotherapy can significantly improve the clinical effect, maintain the stability of the body's immune function and reduce the incidence of toxic and side reactions.

Key words: Guizhi Fuling decoction, advanced cervical cancer, clinical efficacy, toxic and side reactions

中图分类号:

R287

常忠莲, 盛晓滨, 石新兰, 韦薇. 桂枝茯苓汤辨证加味对晚期宫颈癌化学药物治疗患者的增效减毒作用[J]. 首都医科大学学报, 2018, 39(4): 596-601.

Chang Zhonglian, Sheng Xiaobin, Shi Xinlan, Wei Wei. Effect of synergism and attenuation of Guizhi Fuling decoction in patients with advanced cervical cancer treated with chemotherapy[J]. Journal of Capital Medical University, 2018, 39(4): 596-601.

参考文献

[1] Niibe Y, Onda T, Matsuo K, et al. Phase Ⅱ study of concurrent chemoradiotheapy using nedaplatin for locally advanced uterine cervical carcinoma(KGROG0501):final results[J]. Anticancer Res, 2017, 37(12):6983-6988.
[2] 刘少晓, 程晓燕, 郑红枫,等. 紫杉醇联合顺铂新辅助治疗局部晚期宫颈癌的临床疗效及安全性评价[J]. 中国临床药理学杂志, 2015, 31(6):432-434.
[3] 南方, 陈春华. 中西医结合治疗宫颈癌30例的临床疗效研究[J]. 世界中西医结合杂志, 2015, 10(11):1586-1588.
[4] 覃业语, 韦知樱, 韩方璇. 扶正固本汤联合化疗治疗宫颈癌临床疗效及安全性分析[J]. 广州中医药大学学报, 2016, 33(3):321-324.
[5] 李克光, 杨百茀, 殷品之, 等. 金匮要略讲义[M].上海:上海科学技术出版社,1985:229.
[6] 明松林, 刘燕, 杨铁柱,等. 桂枝茯苓汤对乳腺癌细胞株线粒体凋亡途径相关蛋白和细胞周期的影响[J]. 中医药导报, 2015, 45(17):23-26.
[7] 张敏. 妇科肿瘤学[M]. 北京:科学技术文献出版社, 2013:56-57.
[8] 李佩文, 崔慧娟. 实用中西医结合肿瘤内科学[M]. 北京:中国中医药出版社, 2007:31-32.
[9] 杨英珍, 袁亚萍,吕银,等.宫颈癌同步放化疗患者抑郁状况及其影响因素[J].中华肿瘤防治杂志,2017,24(23):1619-1623.
[10] 刘淑荣, 廖革望.局部晚期宫颈癌化疗联合放疗最佳模式探讨[J].中华肿瘤防治杂志,2017,24(3):196-200.
[11] Yavas G, Yavas C, Inan G. Locally advanced squamous cell cervical cancer in a patient with septate uterus[J]. J Contemp Brachytherapy, 2017, 9(5):487-489.
[12] 权丽丽. 紫杉醇联合顺铂辅助治疗中晚期宫颈癌近期疗效与安全性的Meta分析[J]. 中国药房, 2015, 26(24):3389-3392.
[13] 简小兰, 蒋益兰, 曾瀚,等. 中医综合治疗对Ⅲ~Ⅳ期宫颈癌证候积分的影响[J]. 山东中医药大学学报, 2016, 40(6):514-517.
[14] 黄相艳. 桂枝茯苓丸加减配合西药治疗晚期卵巢癌患者临床疗效[J]. 陕西中医, 2017, 38(5):643-645.
[15] 李笠, 高树苓. 米非司酮联合桂枝茯苓胶囊治疗子宫肌瘤患者的疗效分析[J]. 中国肿瘤临床与康复, 2015, 22(1):62-65.
[16] 李文静, 李雪岩, 崔涛,等. 莪术-三棱药对合煎液对大鼠子宫肌瘤的防治作用及机制研究[J]. 中国药房, 2017, 28(19):2609-2612.
[17] Sharma M, Khan R, Aggarwal M, et al. Modulatory effects of chemoradiation on angiogenic factors and laminin in cervical cancer:link with treatment response[J]. Asian Pac J Cancer Prev, 2017, 18(11):2937-2944.
[18] 叶威静, 赵楚楚, 朱雪琼. 桂枝茯苓胶囊治疗子宫肌瘤疗效的研究进展[J]. 医学研究杂志, 2015, 44(11):15-17.
[19] 江益平, 吴秀, 李娜,等. 桂枝茯苓胶囊及其活性成分组合物免疫调节活性及其机制研究[J]. 中国中药杂志, 2015, 40(15):3068-3071.
[20] 刘亚玮, 毕丽鑫, 赵磊. 黄芪注射液辅助治疗耐多药肺结核的临床效果及对免疫功能的影响[J]. 现代医学, 2016, 18(4):462-466.
[21] 殷红岩, 杨娥, 梁江红,等. 桂枝茯苓丸干预裸鼠上皮性卵巢癌的机制研究[J]. 国际中医中药杂志, 2016, 38(9):831-836.
[22] 张珍珍, 张新庄, 李娜,等. 桂枝茯苓胶囊及其活性成分组合物抗炎作用与机制研究[J]. 中国中药杂志, 2015, 40(6):993-998.
[23] 尚伟庆. 黄芪当归合剂对肾病综合征患者肾功能、炎症机制及疗效的影响[J]. 中华中医药学刊, 2017, 35(5):1339-1341.

桂枝茯苓汤辨证加味对晚期宫颈癌化学药物治疗患者的增效减毒作用

Effect of synergism and attenuation of Guizhi Fuling decoction in patients with advanced cervical cancer treated with chemotherapy

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 13

编辑推荐

Metrics

本文评价

[1]	鄢丹. 临床生物特征谱学:中药质量与临床合理用药评价——鄢丹教授[J]. 首都医科大学学报, 2020, 41(5): 773-777.
[2]	许庆庆, 段甦, 王向东, 张罗. 鼻中隔偏曲矫正对变应性鼻炎患者治疗效果的Meta分析[J]. 首都医科大学学报, 2018, 39(6): 928-932.
[3]	于迎, 庄红艳, 尹冬青, 杜渐, 杨静, 贾竑晓. 中医体质类型与抗精神病药物不良反应的关系研究[J]. 首都医科大学学报, 2018, 39(2): 204-208.
[4]	刘俊华, 王勇, 王颜颜, 王晓民. 深部脑磁刺激对帕金森病模型大鼠运动症状治疗的安全性评价[J]. 首都医科大学学报, 2017, 38(2): 260-267.
[5]	张勇, 陈文明, 周合冰. 193例成人免疫性血小板减少症临床分析[J]. 首都医科大学学报, 2014, 35(5): 560-565.
[6]	蒋雪云, 张颖洁, 赵明. 超黄金治疗期的缺血性中风大鼠模型、治疗模式及疗效表述[J]. 首都医科大学学报, 2014, 35(1): 108-112.
[7]	王宇, 孔超, 鲁世保, 海涌, 王庆一, 藏磊, 孟祥龙. 腰椎人工椎间盘置换术不同适应证的临床疗效对比[J]. 首都医科大学学报, 2013, 34(2): 264-269.
[8]	康勋;李珊;谢铮铮;赵艳杰;姜妮;周蕾;李文斌. 恶性脑胶质瘤同步放化疗中替莫唑胺化疗的不良反应及对策[J]. 首都医科大学学报, 2012, 33(5): 589-593.
[9]	简希尧;简榕;利旭辉;廖晓辉;郭宁宁. 复方甘草酸苷联合利巴韦林治疗重型麻疹的临床疗效研究[J]. 首都医科大学学报, 2012, 33(4): 513-515.
[10]	张利勇;王威;王保国. 丙泊酚不良反应的多中心和大样本调查[J]. 首都医科大学学报, 2006, 27(2): 255-257.
[11]	焦希平;史中华;王保国;董佳;刘敏. 罗库溴铵用于气管插管的临床观察[J]. 首都医科大学学报, 2005, 26(4): 495-497.
[12]	王育琴;张建;王香平;王力红;刘佑琴;魏嘉平;冯明;聂秀红;杨强;张泰昌;李宗信;王克杰;续大田;韩玫;李坤成;尹建国;王立;吴晓光;汤哲. SARS患者使用糖皮质激素的不良反应及其相关影响因素研究[J]. 首都医科大学学报, 2003, 24(4): 447-450.
[13]	徐宝荣. 倍欣治疗60例2型糖尿病的临床观察[J]. 首都医科大学学报, 2001, 22(3): 230-231.